ReviewExpert opinion on drug metabolism & toxicology2010
Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development.
Review in Expert opinion on drug metabolism & toxicology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 41 citations in OpenAlex.
- An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.Cancer chemotherapy and pharmacology · 2024Trial
- The effect of an adenosine AFluids and barriers of the CNS · 2018Trial
- A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.European journal of cancer (Oxford, England : 1990) · 2013Trial
- Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850).Pharmaceutical research · 2024Article
- Quantitative monitoring and modelling of retrodialysis drug delivery in a brain phantom.Scientific reports · 2023Article
- Methods for intratumoral microdialysis probe targeting and validation in murine brain tumor models.Journal of neuroscience methods · 2021Article
- Measuring Histamine and Cytokine Release from Basophils and Mast Cells.Methods in molecular biology (Clifton, N.J.) · 2020Article
- Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Biochemical changes in the injured brain.World journal of biological chemistry · 2017Article
- Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications.Frontiers in oncology · 2015Review
- A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent.Journal of neuro-oncology · 2014Article
- Noninvasive fluorescence resonance energy transfer imaging of in vivo premature drug release from polymeric nanoparticles.Molecular pharmaceutics · 2013Article
- Blood-based biomarkers for malignant gliomas.Journal of neuro-oncology · 2013Review
- Which drug or drug delivery system can change clinical practice for brain tumor therapy?Neuro-oncology · 2013Review
- Chemoprotection in glioblastoma therapy: reality or a dream?CNS oncology · 2012Article
- Clinical microdialysis in neuro-oncology: principles and applications.Chinese journal of cancer · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
importance of the fieldmany promising targeted agents and combination therapies are being investigated for brain cancer. However, the results from recent clinical trials have been disappointing. A better understanding of the disposition of drug in the brain early in drug development would facilitate appropriate channeling of new drugs into brain cancer clinical trials. AREAS COVERED IN THIS REVIEW: barriers to successful drug activity against brain cancer and issues affecting intratumoral drug concentrations are reviewed. The use of the microdialysis technique for extracellular fluid (ECF) sampling and its application to drug distribution studies in brain are reviewed using published literature from 1995 to the present. The benefits and limitations of microdialysis for performing neuorpharmacokinetic (nPK) and neuropharmacodynamic (nPD) studies are discussed. WHAT THE READER WILL GAIN: the reader will gain an appreciation of the challenges involved in identifying agents likely to have efficacy in brain cancer, an understanding of the general principles of microdialysis, and the power and limitations of using this technique in early drug development for brain cancer therapies. TAKE HOME MESSAGE: a major factor preventing efficacy of anti-brain cancer drugs is limited access to tumor. Intracerebral microdialysis allows sampling of drug in the brain ECF. The resulting nPK/nPD data can aid in the rational selection of drugs for investigation in brain tumor clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.